SGCG and precursor B-cell acute lymphoblastic leukemia: According to several reports, CRLF2-r B-ALL exhibits a variable response to type I JAKi, suggesting that inhibiting a single JAK1/2 is an insufficient therapeutic approach [16,24,34].